NCT01257607

Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 and 5% MIM-D3 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (actual)
• Sponsor: Mimetogen Pharmaceuticals USA, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to compare the safety and efficacy of 1% MIM-D3 and 5% MIM-D3 to placebo for the treatment of the signs and symptoms of dry eye.

Conditions

• Dry Eye

Interventions

Type	Name	Description
DRUG	MIM-D3 Ophthalmic Solution	28 Days, BID
DRUG	Placebo Ophthalmic Solution	28 Days, BID

Timeline

• Start date: 2010-11-01
• Primary completion: 2011-05-01
• Completion: 2011-05-01
• First posted: 2010-12-09
• Last updated: 2019-08-19

Locations

1 site across 1 country: United States